{"id":384206,"date":"2023-12-15T19:06:54","date_gmt":"2023-12-16T00:06:54","guid":{"rendered":"https:\/\/platohealth.ai\/emas-chmp-green-lights-casgevy-skyclarys-and-velsipity\/"},"modified":"2023-12-18T02:16:01","modified_gmt":"2023-12-18T07:16:01","slug":"emas-chmp-green-lights-casgevy-skyclarys-and-velsipity","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/emas-chmp-green-lights-casgevy-skyclarys-and-velsipity\/","title":{"rendered":"EMA\u2019s CHMP green-lights Casgevy, Skyclarys and Velsipity","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

DATA GRAPHICS | Data Byte<\/p>\n

\n
\n
\n

December highlights also include confirmation of non-renewal for Blenrep, plus recommendations for two therapies for neglected tropical diseases<\/h2>\n

\n By <\/span>Gunjan Ohri, Data Content Analyst  <\/span><\/span>\n<\/p>\n

December 16, 2023 12:06 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

At its December meeting, EMA\u2019s CHMP recommended approval of three new medicines, Casgevy, Skyclarys and Velsipity, and label extensions for four. The agency also confirmed its non-renewal of Blenrep.<\/p>\n

Just weeks after Casgevy exagamglogene autotemcel became the world\u2019s first<\/a> gene editing therapy via approval in the U.K., CHMP has recommended conditional approval of Casgevy for transfusion-dependent \u03b2-thalassemia and sickle cell disease. …<\/p>\n